Gathering Informations

Applications

ZiP has built a facility to manufacture point-of-care diagnostic tests for Australian domestic applications and low to middle-income countries. This includes SARS-CoV-2 (COVID-19), and sexually transmitted diseases (chlamydia and gonorrhoea). ZiP plans to extend the test menu to include viral hepatitis, respiratory viruses, vector-borne diseases and tuberculosis.

SARS-CoV-2 is a coronavirus that was first reported in 2019, Wuhan, Hubei Province, China and has since rapidly spread globally. SARS-CoV-2 infection causes a spectrum of clinical disease: asymptomatic to severe disease.

ZiP is bringing a high sensitivity molecular test system for SARS-CoV-2 to domestic high-volume production. Advantages of this system includes:

  • Direct detection of SARS-CoV-2 virus

  • Deployable at PoC (i.e., not lab-based)

  • Additional gene target for test result confirmation

  • Takes nasal, throat and saliva swab samples

  • Sample to result within 15-30 minutes

  • Sensitivity comparable to PCR

  • Simple work flow

  • Low cost test

  • Secure, encrypted data

ZiP-CoVx-P2 Diagnostic

Detecting: SARS-COV-2 (COVID-19)
Test System: ZiP-P2

20211117_P2 3.jpg

ZiP-CTNG-H4 Diagnostic

Detecting: Chlamydia trachomatis & Neisseria gonorrhoeae
Test System: ZiP-H4

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) cause some of the most prevalent sexually transmitted diseases in both male and women. Uncomplicated CT and NG infections can be treated and cured with antibiotics. Untreated infections can result in serious complications.

ZiP is bringing a high sensitivity molecular test system for Chlamydia trachomatis & Neisseria gonorrhoeae to low-middle income countries with the goal of improving syndromic patient management and facilitating appropriate antibiotic use to minimise antimicrobial resistance. Advantages of this system includes:

  • Direct detection of Chlamydia trachomatis & Neisseria gonorrhoeae

  • Deployable at PoC (i.e., not lab-based)

  • Additional gene target for Neisseria gonorrhoeae for test result confirmation

  • Takes urine and genital swab samples

  • Sample to result within 10-30 minutes

  • Sensitivity comparable to PCR

  • Self-contained, fully-sealed point-of-care cartridge

  • Simple work flow with integrated sample preparation and dispensing

  • Low cost test

  • Secure, encrypted data

ZiP-BBV-H4 Diagnostic

Detecting: Hepatitis B Virus, Hepatitis C Virus & Human Immunodeficiency Virus
Test System: ZiP-H4

EARLY STAGE DEVELOPMENT

Hepatitis B and hepatitis C, together with HIV (human immunodeficiency virus) are the most common blood-borne viruses in Australia. Hepatitis C is curable, whereas hepatitis B and HIV require lifelong treatment. Left untreated, consequences can be fatal.

ZiP has begun development of a high sensitivity molecular test system for hepatitis B, hepatitis C and HIV. This will allow low-cost simultaneous detection and differentiation between these viruses for rapid diagnoses and correct treatment. Advantages of this system includes:

  • Direct detection of Hepatitis B Virus, Hepatitis C Virus (all genotypes) & HIV

  • Deployable at PoC (i.e., not lab-based)

  • Takes fingerprick plasma and blood samples

  • Sample to result within 30 minutes

  • Sensitivity comparable to PCR

  • Self-contained, fully-sealed point-of-care cartridge

  • Simple work flow with integrated sample preparation and dispensing

  • Low cost test

  • Secure, encrypted data